Zeria Pharmaceutical Co., Ltd.

Tokyo Stock Exchange 4559.T

Zeria Pharmaceutical Co., Ltd. EPS (Diluted) for the year ending March 31, 2024: USD 1.16

Zeria Pharmaceutical Co., Ltd. EPS (Diluted) is USD 1.16 for the year ending March 31, 2024, a 9.76% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.
  • Zeria Pharmaceutical Co., Ltd. EPS (Diluted) for the year ending March 31, 2023 was USD 1.06, a 46.44% change year over year.
  • Zeria Pharmaceutical Co., Ltd. EPS (Diluted) for the year ending March 31, 2022 was USD 0.72, a 17.03% change year over year.
  • Zeria Pharmaceutical Co., Ltd. EPS (Diluted) for the year ending March 31, 2021 was USD 0.62, a 5.79% change year over year.
  • Zeria Pharmaceutical Co., Ltd. EPS (Diluted) for the year ending March 31, 2020 was USD 0.58, a -7.18% change year over year.
Key data
Date EPS (Diluted) Shares (Diluted, Weighted) Shares (Basic, Weighted) Revenue
Market news
Loading...
SV Wall Street
Tokyo Stock Exchange: 4559.T

Zeria Pharmaceutical Co., Ltd.

CEO Mr. Sachiaki Ibe
IPO Date Jan. 1, 2001
Location Japan
Headquarters 10-11 Nihonbashi Kobuna-cho
Employees 1,777
Sector Healthcare
Industries
Description

Zeria Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, and reagents in Japan and internationally. It also provides cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, and measuring and analytical equipment. The company offers products in the gastrointestinal field, including therapeutic agents for functional dyspepsia, ulcerative colitis, Crohn's disease, and gastritis and ulcers; zinc containing anti-ulcerants; oral bowel cleansing agents; laxatives; therapeutic agents for hypophosphatemia; long-acting calcium channel blockers; oral NSAID; anti-leukopenia after radiotherapy products; sclerosing agent for varicose veins; anti-inflammatory topical blood circulation enhancers; non-steroidal anti-inflammatory ophthalmic solutions; absorbable topical hemostat products; and proton pump inhibitors. In addition, it offers consumer healthcare products, such as nutritional health drugs, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, hemorroidal remedies, dermal remedies, quasi-drugs/cosmetics, nutrient tonics, and food for specified health uses. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Tokyo, Japan.

Similar companies

4521.T

Kaken Pharmaceutical Co., Ltd.

USD 27.19

-2.00%

4540.T

Tsumura & Co.

USD 29.51

-0.48%

4551.T

Torii Pharmaceutical Co., Ltd.

USD 32.09

-0.98%

4547.T

Kissei Pharmaceutical Co., Ltd.

USD 25.51

-0.96%

4516.T

Nippon Shinyaku Co., Ltd.

USD 24.26

-0.77%

StockViz Staff

February 2, 2025

Any question? Send us an email